Dr. Durrant is the founder of Taran Therapeutics and brings experience as a senior leader at several global pharmaceuticals companies, extensive end-to-end product development, launch and commercialization expertise, including 5 global blockbusters. He has significant biotech, operating executive as CEO, interim CFO, CMO and board member of both public and private companies.

Dr. Durrant has developed a deep understanding of lenzilumab and ifabotuzumab, having worked on these product for 10 years, first as Chairman and CEO of Humanigen from January 2016 and then later acquiring these products under Taran.

He earned his medical degree from the Welsh National School of Medicine, Cardiff, UK and various post-graduate medical diplomas and memberships in the UK and his MBA from Henley Management College, Oxford. He was a regional Entrepreneur of the Year, a Fellow of the Learned Society of Wales and a Professor at the Cardiff University School of Medicine.

He has authored or co-authored papers which have appeared in peer-reviewed medical journals and is the owner or inventor of dozens of patents.